Device type · JFM
Enzymatic Method, Bilirubin
Last checked: Nov 20, 2026Source: openFDAMethods & limitations
Product code
JFM
Clinical Chemistry
Device class
Class II
FDA decisions since 2015
3
510(k), De Novo and PMA
Adverse event reports
1
Received Nov 1, 2025 to Nov 20, 2026
How FDA classifies it
- Device type
- Enzymatic Method, Bilirubin
- Product code
- JFM
- Device class
- Class II
- Review panel
- Clinical Chemistry
- Regulation
- 21 CFR 862.1110
- Specialty
- Laboratory Medicine & Pathology
- FDA record
- Classification database entry for JFM
Latest FDA decisions
Siemens Healthcare Diagnostics, Inc.
K170065 · Decided Mar 9, 2017 · 59 days after receipt
Device type: Enzymatic Method, Bilirubin (JFM) · Laboratory Medicine & Pathology
- Direct Bilirubin510(k)
K152343 · Decided Feb 16, 2016 · 181 days after receipt
Device type: Enzymatic Method, Bilirubin (JFM) · Laboratory Medicine & Pathology
- Total Bilirubin510(k)
K152344 · Decided Jan 28, 2016 · 162 days after receipt
Device type: Enzymatic Method, Bilirubin (JFM) · Laboratory Medicine & Pathology
Reports received
1
Received Nov 1, 2025 to Nov 20, 2026
Malfunction reports
0
0.0% of reports
Injury reports
1
100% of reports
Death reports
0
0.0% of reports
Adverse event reports received per month
By the date FDA received each report, stacked by event type. The newest month is incomplete.
- Malfunction
- Injury
- Death
- Other
View as table
| Month | Malfunction | Injury | Death | Other |
|---|---|---|---|---|
| Dec 23 | 0 | 0 | 0 | 0 |
| Jan 24 | 0 | 0 | 0 | 0 |
| Feb 24 | 0 | 0 | 0 | 0 |
| Mar 24 | 0 | 0 | 0 | 0 |
| Apr 24 | 0 | 0 | 0 | 0 |
| May 24 | 0 | 0 | 0 | 0 |
| Jun 24 | 0 | 0 | 0 | 0 |
| Jul 24 | 0 | 0 | 0 | 0 |
| Aug 24 | 0 | 0 | 0 | 0 |
| Sep 24 | 1 | 0 | 0 | 0 |
| Oct 24 | 0 | 0 | 0 | 0 |
| Nov 24 | 0 | 0 | 0 | 0 |
| Dec 24 | 0 | 0 | 0 | 0 |
| Jan 25 | 0 | 0 | 0 | 0 |
| Feb 25 | 0 | 0 | 0 | 0 |
| Mar 25 | 0 | 0 | 0 | 0 |
| Apr 25 | 0 | 0 | 0 | 0 |
| May 25 | 0 | 0 | 0 | 0 |
| Jun 25 | 0 | 0 | 0 | 0 |
| Jul 25 | 0 | 0 | 0 | 0 |
| Aug 25 | 0 | 0 | 0 | 0 |
| Sep 25 | 0 | 0 | 0 | 0 |
| Oct 25 | 0 | 0 | 0 | 0 |
| Nov 25 | 0 | 0 | 0 | 0 |
| Dec 25 | 0 | 1 | 0 | 0 |
| Jan 26 | 0 | 0 | 0 | 0 |
| Feb 26 | 0 | 0 | 0 | 0 |
| Mar 26 | 0 | 0 | 0 | 0 |
| Apr 26 | 0 | 0 | 0 | 0 |
| May 26 | 0 | 0 | 0 | 0 |
| Jun 26 | 0 | 0 | 0 | 0 |
| Jul 26 | 0 | 0 | 0 | 0 |
| Aug 26 | 0 | 0 | 0 | 0 |
| Sep 26 | 0 | 0 | 0 | 0 |
| Oct 26 | 0 | 0 | 0 | 0 |
| Nov 26 | 0 | 0 | 0 | 0 |
Manufacturers named most often
Last 12 months. Bigger sellers get more reports. This is not a ranking of safety.
Device problems as coded
Last 12 months. FDA's terms. A report can carry several.
- False Positive Result1
- Incorrect, Inadequate or Imprecise Result or Readings1
Patient problems as coded
Last 12 months. FDA's terms. A report can carry several.
- Insufficient Information1
Recent recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
- RANDOX Total Bilirubin.Open, Classified
Z-0501-2024 · Started Oct 11, 2023 · Posted by FDA Dec 6, 2023
Reason given: Randox has had reports of elevated patient results using Plasma (lithium heparin) samples with Total Bilirubin reagent (TBil) Vanadate Oxidation Method.
Cause as FDA categorized it: Device Design
Siemens Healthcare Diagnostics, Inc.
Z-2471-2023 · Started Jul 10, 2023 · Posted by FDA Aug 28, 2023
Reason given: Potential for reagent carryover on the Atellica CH 930 resulting in a positive bias that could impact quality control (QC), patient samples, and calibrator results with from Atellica CH Total Bilirubin_2 (TBil_2), AtellicaCH LDL Cholesterol (LDLC), Atellica CH Gamma-Glutamyl Transferase (GGT) and AtellicaCH HDL...
Cause as FDA categorized it: Under Investigation by firm
Siemens Healthcare Diagnostics, Inc.
Z-2472-2023 · Started Jul 10, 2023 · Posted by FDA Aug 28, 2023
Reason given: Potential for reagent carryover on the Atellica CH 930 resulting in a positive bias that could impact quality control (QC), patient samples, and calibrator results with from Atellica CH Total Bilirubin_2 (TBil_2), Atellica CH LDL Cholesterol (LDLC), Atellica CH Gamma-Glutamyl Transferase (GGT) and Atellica CH HDL...
Cause as FDA categorized it: Under Investigation by firm
6 more recall records with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.